Loading clinical trials...
Loading clinical trials...
HYPOTHESIS AND SAMPLE SIZE The tumor delineated by FDG-PET is significantly different from the delineation achieved by MR T1 contrast weighted images in glioblastoma; expecting a standard error of 12....
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Medanta Institute of Clinical Research
NCT05902169 · Glioblastoma, Recurrent Glioblastoma, and more
NCT07003542 · Glioblastoma, Brain Tumor
NCT05303467 · Glioblastoma Multiforme, Recurrent Glioblastoma
NCT07464925 · Glioblastoma Multiforme of Brain, Glioma, and more
NCT07274397 · Glioblastoma, Brain Tumors, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions